Sermorelin

FDA records document Geref and its discontinuation. A historical approval or a determination that a product was not withdrawn for safety or effectiveness reasons is not a current approval of every product containing the ingredient. It also does not validate every proposed indication. ^{1, 2}

A compounded preparation has its own ingredients, route and quality considerations. Patient-specific 503A preparations are compounded by a state-licensed 503A pharmacy pursuant to a patient-specific prescription. They are not FDA-approved. A pharmacy’s use of sermorelin cannot be described as dispensing Geref unless that exact product identity is established. ³

The relevant question is whether controlled research in the proposed population demonstrates a meaningful benefit that outweighs harms. A hormone response, a prior pediatric indication or an ingredient’s long history cannot answer that question by itself. This reference does not establish a longevity or performance protocol.

Geref products were approved historically for diagnostic and pediatric growth-related uses, then discontinued. FDA later determined the discontinuation was not for safety or effectiveness reasons, but that finding does not mean Geref is currently marketed or that today's compounded sermorelin is the approved product. Historical labels also do not establish anti-aging, sleep, fat-loss or muscle-building indications. Every status statement should name the finished product, route, indication and date rather than calling sermorelin generally FDA-approved. ^{1, 2}

A compounded sermorelin injection is an unapproved finished drug. If it is proposed for an individual medical need, ask for the exact substance, concentration, pharmacy, preparation and storage instructions. FDA does not review a compounded preparation for safety, effectiveness or quality before marketing. Sterility, peptide impurities, aggregation and consistent potency are separate from whether the molecule can stimulate growth-hormone release. A pharmacy prescription does not establish a longevity outcome or make a proprietary peptide blend equivalent to historical Geref. ^{2, 3}

A proposal should identify the diagnosed condition, intended clinical outcome, duration and stopping rule. Changes in growth hormone or IGF-1 are biomarkers, not proof of improved function or longer life. Headache, flushing, dizziness, swelling, joint symptoms, numbness, glucose changes or injection reactions warrant review. Combining sermorelin with ipamorelin or other secretagogues adds uncertain exposure and requires direct evidence for the complete intervention. Do not use historical pediatric or diagnostic instructions to create a wellness dosing plan. ^{1, 2, 3}

Historical pediatric growth uses involved diagnosed conditions and specialist monitoring. They cannot be generalized to adults with age-related hormone changes, fatigue or body-composition goals. Normal growth-hormone physiology changes with age, and restoring a laboratory value to a youthful range is not an approved treatment target. Adult claims require adult clinical outcomes and long-term safety evidence for the exact current formulation. ^{1, 2, 3}